Biodesix (NASDAQ:BDSX) rose 10.43% on June 23, 2026, as higher revenue outlook extended lung diagnostics momentum, with shares closing at $19.16.

Key Highlights

  • Rose 10.43%: Biodesix closed at $19.16 on June 23 after moving $1.81 per share.
  • Catalyst: During the session, higher revenue outlook extended lung diagnostics momentum.
  • Company: Biodesix develops blood-based and molecular diagnostic tests used in lung disease and cancer care.
  • Session: The stock finished at $19.16, while the available company record showed a disclosed catalyst for the move.

Biodesix (NASDAQ:BDSX) rose 10.43% on June 23, 2026, closing at $19.16 after a $1.81 per-share move. The session’s advance came as higher revenue outlook extended lung diagnostics momentum, based on the available company disclosures and trading context.

The advance continued the positive momentum established following Biodesix's strong first-quarter results, which showed meaningful revenue growth in its lung diagnostic testing business, and an upward revision to its 2026 revenue outlook. Biodesix develops molecular diagnostics for lung disease, with its Nodify lung nodule risk assessment tests gaining broader clinical adoption.

Biodesix develops blood-based and molecular diagnostic tests used in lung disease and cancer care.

No additional clinical or financial announcement was filed during the June 23 session. The advance followed residual optimism from the prior earnings catalyst.

The June 23 move did not follow a second earnings release during the session. Instead, the stock continued to reflect information from the earlier financial update, including the revenue, guidance or operating indicators described by the company.

The $19.16 close placed the shares 10.43% above the prior session. The available record did not show a separate change to the previously issued outlook on June 23.

For the June 23 close, the defining facts were the 10.43% advance, the $19.16 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.